uniQure (NASDAQ:QURE) Stock Rating Upgraded by Wall Street Zen

uniQure (NASDAQ:QURE) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday.

QURE has been the subject of a number of other reports. HC Wainwright reiterated a “buy” rating and issued a $70.00 price objective on shares of uniQure in a report on Thursday, May 29th. Chardan Capital decreased their price objective on shares of uniQure from $38.00 to $35.00 and set a “buy” rating for the company in a report on Tuesday, July 29th. Cantor Fitzgerald set a $47.00 price objective on shares of uniQure in a report on Wednesday. Finally, Guggenheim reiterated a “buy” rating and issued a $28.00 price objective on shares of uniQure in a report on Monday, May 12th. Four investment analysts have rated the stock with a hold rating, six have issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $36.55.

uniQure Stock Performance

Shares of NASDAQ QURE opened at $13.69 on Friday. The business’s 50-day moving average price is $14.83 and its two-hundred day moving average price is $13.68. The company has a debt-to-equity ratio of 1.53, a current ratio of 9.98 and a quick ratio of 9.98. uniQure has a one year low of $4.45 and a one year high of $19.18. The company has a market capitalization of $751.17 million, a P/E ratio of -3.49 and a beta of 0.11.

uniQure (NASDAQ:QURE) last issued its earnings results on Tuesday, July 29th. The biotechnology company reported ($0.69) EPS for the quarter, beating analysts’ consensus estimates of ($0.89) by $0.20. uniQure had a negative return on equity of 1,010.74% and a negative net margin of 1,387.98%. The firm had revenue of $5.26 million for the quarter, compared to the consensus estimate of $5.00 million. Analysts anticipate that uniQure will post -3.75 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Madhavan Balachandran sold 2,112 shares of the stock in a transaction that occurred on Friday, June 20th. The stock was sold at an average price of $14.45, for a total value of $30,518.40. Following the completion of the sale, the director directly owned 37,697 shares of the company’s stock, valued at approximately $544,721.65. This represents a 5.31% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Jeannette Potts sold 4,670 shares of the stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $15.14, for a total value of $70,703.80. Following the completion of the sale, the insider directly owned 115,073 shares of the company’s stock, valued at $1,742,205.22. This represents a 3.90% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 22,144 shares of company stock worth $322,426 in the last ninety days. 4.79% of the stock is owned by insiders.

Institutional Investors Weigh In On uniQure

Several hedge funds have recently modified their holdings of QURE. KLP Kapitalforvaltning AS bought a new stake in shares of uniQure in the 2nd quarter worth approximately $117,000. ADAR1 Capital Management LLC bought a new stake in shares of uniQure in the 4th quarter worth approximately $177,000. Mraz Amerine & Associates Inc. bought a new stake in shares of uniQure in the 1st quarter worth approximately $106,000. Teacher Retirement System of Texas bought a new stake in shares of uniQure in the 2nd quarter worth approximately $151,000. Finally, Wells Fargo & Company MN lifted its position in shares of uniQure by 13.9% in the 4th quarter. Wells Fargo & Company MN now owns 12,294 shares of the biotechnology company’s stock worth $217,000 after acquiring an additional 1,503 shares during the period. 78.83% of the stock is owned by institutional investors.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.